



**Workshop**

# **Broad-spectrum anti-viral therapeutics:**

a key tool for  
pandemic preparedness

**Agenda**

Brussels, 22-23 November 2022

## Day 1 - Tuesday 22 November

---

09:00-09:30 **Registration and welcome coffee & tea**

---

09:30-09:45 **Welcome & Opening remarks**

Irene Norstedt, EC/RTD

Wolfgang Philipp, EC/HERA

Eric Snijder, Leiden University Medical Centre

---

09:45-10:05 **1. Keynote: The role of antivirals in epidemic preparedness and response**

Peter Piot, Special Advisor to the President of the European Commission

**2. Broad-spectrum antivirals in pandemic preparedness & response:  
Current and future policy actions**

Moderation: Ágnes Molnár, EC/HERA

---

10:05-10:25 **Broad-spectrum antivirals in pandemic preparedness and response:  
Perspective from the World Health Organization**

Nahoko Shindo, World Health Organization

---

10:25-10:45 **Policy implications of the COVID-19 pandemic in Europe**

Ágnes Molnár, EC/HERA

---

10:45-11:05 **Cracking the Code: Advanced development and licensure of the elusive broad- spectrum antiviral drug**

Robert Johnson, BARDA

---

11:05-11:35 **Coffee & tea break**

---

**3. Pre-clinical research of broad-spectrum antivirals**

Moderation: Barbara Kerstiëns, EC/RTD & Eric Snijder, Leiden University Medical Centre

---

11:35-11:50 **Towards broad(er)-spectrum antiviral agents**

Johan Neyts, Rega Institute for Medical Research, KU Leuven

---

11:50-12:05 **The Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern, multi-disciplinary research for anti-viral development**

Cristina Cassetti, DMID/NIAID/NIH

---

12:05-12:20 **Bolstering local innovative drug discovery capabilities for pandemic preparedness:  
The Holistic Drug Discovery and Development (H3D) Centre in South Africa**

Kelly Chibale, H3D

---

12:20-12:30 **Industry pipeline for broad-spectrum antivirals**

Magda Chlebus, EFPIA

---

12:30-12:40 **Stimulating innovation for pandemic preparedness: the Blue Knight initiative**

Ruxandra Draghia Akli, Janssen Pharmaceutical Companies of Johnson & Johnson

---

12:40-13:30 **Panel discussion**

---

*Challenges and potential solutions to consider in research of broad-spectrum antiviral agents (e.g. risk for resistance, consideration of combination therapy), gaps to fill.*

Charles Wiysonge, South African Medical Research Council

Timothy Jinks, Wellcome

Miguel Castanho, University of Lisbon

Stephan Becker, University of Marburg

Bernadett Pályi, ISIDORE

Magda Chlebus, EFPIA

---

13:30-14:30	Lunch
<b>4. Clinical research environment</b> Moderation: Bola Jones (CEPI) & Jacques Demotes (ECRIN)	
14:30-14:45	Clinical and research experience from the European clinical trials in emergencies Marius Trøseid, Oslo University Hospital
14:45-14:55	Fast clinical assessment of antivirals in a crisis response: The AGILE clinical trial platform Saye Khoo, University of Liverpool
14:55-15:05	Clinical research for COVID-19 antivirals: Experience from South Africa Charles Wiysonge, South African Medical Research Council
15:05-15:15	Regulatory consideration for clinical development of broad-spectrum antiviral agents Marco Cavaleri, European Medicines Agency
15:15-15:45	<b>Panel discussion</b> <i>What is needed to ensure an enabling clinical research environment for broad- spectrum anti-virals in an epidemic or pandemic preparedness &amp; response context?</i> Sanjay Bhagani, Member of JAAM Saye Khoo, University of Liverpool Marjolein Hensgens, University Medical Centre Utrecht Jens Lundgren, Rigshospitalet, University of Copenhagen
15:45-16:15	Coffee & tea break
<b>5. Availability &amp; Access</b> Moderation: Olivier Girard, EC/HERA	
16:15-16:25	Influenza and SARS-CoV-2 virus characterisation in the EU/EEA Eeva Broberg, ECDC
16:25-16:35	Ensuring the last mile: From production to patients Catherine Decouttere, KU Leuven
16:35-16:45	Prioritisation of threats and medical countermeasures Ágnes Molnár, EC/HERA
16:45-16:55	Manufacturing capacities for pandemic preparedness Isabel Holmquist & Siri Hauge, EC/HERA
16:55-17:10	Q&A and short discussion
<b>6. Global context</b> Moderation: Gabriella Fesus, EC/INTPA & Kelly Chibale, H3D	
17:10-17:20	The Pandemic Antiviral Discovery (PAD) initiative Robert Jordan, Bill & Melinda Gates Foundation
17:20-17:30	Trial implementation in low and middle income contexts Fadima Cheick Haidara, Centre pour le Développement des Vaccins du Mali (CVD-Mali) Online
17:30-17:40	Tools to promote global access to new medicines Tajudeen Raji, Africa Centres for Disease Control and Prevention
17:40-17:50	One Health perspective Marisa Peyre, PREZODE

---

17:50-18:00 Broad-spectrum antivirals in pandemic preparedness: the economics of a rapid emergency response

Rachel Glennerster, University of Chicago

---

18:00-18:10 Research funding coordination for pandemic preparedness and response

Charu Kaushic, GloPID-R (online)

---

18:10-18:30 Q&A and short discussion

---

18:30-19:00 Break

---

19:00-20:30 **Networking reception**

---

## Day 2 - Wednesday 23 November

---

08:30-09:00 **Welcome coffee & tea**

---

09:00-09:15 **Conclusions Day 1**

Irene Norstedt, EC/RTD & Wolfgang Phillip, EC/HERA

---

09:15-10:15 **7. High-level panel discussion: Broad-spectrum antivirals in the pandemic preparedness and response toolbox**

Moderation: Irene Norstedt, EC/RTD & Wolfgang Phillip, EC/HERA

*Capitalising on the discussions of Day 1, what is the role of broad-spectrum antivirals in the context of pandemic preparedness and response; what is needed to make sure that broad-spectrum can become an accomplished tool in preparing for and responding to an epidemic or pandemic.*

Peter Piot, Special Advisor to the President of the European Commission

Nahoko Shindo, World Health Organization

Tajudeen Raji, Africa Centres for Disease Control and Prevention

Johan Neyts, Rega Institute for Medical Research, KU Leuven

Marco Cavaleri, European Medicines Agency

Nathalie Strub-Wourgaft, DNDi

Christopher Houchens, BARDA

---

10:15-10:25 **8. Towards a roadmap**

Moderation: Edit Szepessy, EC/HERA & Evelyn Depoortere, EC/RTD

Roadmap strategy: Introduction

---

10:25-10:50 **Coffee & tea break**

---

10:50-11:45 **Group discussion**

---

1) Access and availability to broad-spectrum antivirals in the context of prioritising public health needs for pandemic preparedness and response

---

2) Research priorities for ongoing and future work on broad-spectrum antiviral agents

---

11:45-12:20 **Feedback group discussions & roadmap principles**

---

12:20-12:30 **9. Next steps & closing remarks**

Barbara Kerstiëns, EC/RTD & Ágnes Molnár, EC/HERA

---